Migraine Prophylaxis With Clopidogrel Trial

• Status: Recruiting
• Trial end date: 2023-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The underlying mechanisms of association between the right-to-left shunts (RLS) and migraine may concern with platelet aggregation and paradoxical embolization. The aim of the study is to evaluate the prophylactic effectiveness of clopidogrel for migraineurs with RLS.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: First Affiliated Hospital Xi'an Jiaotong University
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• migraine with or without aura diagnosed by a neurologist according to the criteria of the International Headache Society (3nd edition)

• experience a minimum of two migraine attacks per month in a 3-month baseline phase

• without regular use of prophylactic treatments or unresponsive to two and more commonly applied preventive medications

• the presence of RLS confirmed by contrast-enhanced transcranial Doppler

• no positive findings in cranial CT and MRI

Exclusion Criteria:

• other types of headaches

• systemic chronic diseases, cerebrovascular disease, abnormal platelet or liver function

• history of head injury

• other contraindications to clopidogrel treatment